Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Single and Repeat Dose, Dose Escalation Study of AV0328 Administered to Healthy Adult Volunteers

NCT02853617 is registered in ClinicalTrials.gov with Alopexx Vaccine, LLC as lead sponsor.

NCT NCT02853617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02853617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Single and Repeat Dose, Dose Escalation Study of AV0328 Administered to Healthy Adult Volunteers
Lead sponsor
Alopexx Vaccine, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
March 22, 2017
Completion date
April 23, 2018
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pnag-expressing pathogenic microbes vaccine